Mereo BioPharma Group plc

MREO

Mereo BioPharma Group plc

1.99

-0.22

(-9.95%)

Today

As of 4:00 PM Eastern

After Hours:

2.01

0.02

(1.16%)

Options AI - All Directions

Apr 17 Expected Move

See where the options market thinks MREO will move from here.

2025-03-06 09:30:002025-03-17 15:00:002025-03-27 12:30:002025-04-08 10:00:002025-04-17 15:30:00Max LossMax LossProfits7.87Breakeven-3.87Breakeven

Mereo BioPharma Group plc

Market Cap: 308.74 million

PE Ratio: -6.63

Volume: 1.69 million

Sector: Healthcare

Industry: Biotechnology

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.